Corporate Profile for Symbollon Corporation, dated Nov. 27, 1998.

--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-

Published Date:   Nov. 27, 1998

Company Name:     Symbollon Corporation

Address:          37 Loring Drive
                  Framingham, Mass. 01702

Main Telephone
 Number:          508-620-7676

Chief Financial
 Officer:         Paul C. Desjourdy

Investor Relations
 Contact:         Paul C. Desjourdy
 Business number: 508-620-7676

Public Relations
 Contact:         Paul C. Desjourdy

Trading Symbol/
 Exchange:        SYMBA

Industry:         Pharmaceutical Drugs

Company description: Symbollon Corporation is engaged in the development and commercialization of proprietary iodine-based compounds for the prevention and treatment of various human diseases. The company's lead product candidate, IoGen(tm), is currently in Phase II clinical trials for the treatment of fibrocystic breast disease. Fibrocystic breast disease is a benign breast condition affecting approximately 30% of the women of child-bearing age, which

represents in the United States about 24 million women. Publications covering previous independent third party testing utilizing iodine to treat collectively over 1,500 women with fibrocystic breast disease have reported 60% or greater clinical improvement in their breast disease.

The company is also collaborating with Bausch & Lomb Pharmaceuticals and Watson Pharmaceuticals to develop drug compounds based on the company's technology. With Bausch & Lomb, the company is developing new drugs for treating ophthalmic infections. The company is working with Watson to develop applications to treat human skin diseases.